It is currently Thu Apr 24, 2014 2:59 pm

News News of Tecfidera (BG-12, dimethyl fumarate)

Site map of Tecfidera (BG-12, dimethyl fumarate) » Forum : Tecfidera (BG-12, dimethyl fumarate)

Discuss Tecfidera (BG-12, dimethyl fumarate) as an oral treatment for multiple sclerosis.

BG12

Could someone remind me of what BG12 is actually?? I know its fumeric acid or something like that but I read somewhere on this forum that it can be synthesised via a supplement but just can't find the post.
Thanks
Read more : BG12 | Views : 2522 | Replies : 9


Data highlight safety profile of oral MS drug BG-12

Image

The latest data on Biogen Idec Inc.'s (BIIB) experimental multiple-sclerosis pill BG-12 show "favorable safety and tolerability" that support the drug's use as a front-line treatment for MS patients, the biotechnology company said.

Details from the "Confirm" study on BG-12 were set for presentation at an American Academy of Neurology conference Tuesday. The drug is currently under review with U.S. and European regulators and could be approved early next year.
Positive data and high ...
Read more : Data highlight safety profile of oral MS drug BG-12 | Views : 1017 | Replies : 1


Multiple Sclerosis Drug BG-12

Has anybody heard of the drug BG-12..??? Wife had an appointment with her neuro today and is looking to put
her on BG-12. She currently is taking Rebif and doing quite well with the only side affect is the rashes at injection site.
Anyhow, any info would be greatly appreciated.


Thanks,

Bob
Read more : Multiple Sclerosis Drug BG-12 | Views : 2573 | Replies : 4


Biogen files NDA for BG-12

Biogen files new drug application (NDA) for BG-12.

http://www.zacks.com/stock/news/70735/B ... alyst+Blog

Biogen Idec (BIIB) recently announced the submission of a new drug application (NDA) for its oral multiple sclerosis candidate, BG-12. The NDA was based on data from the phase III DEFINE and CONFIRM studies which showed that treatment with BG-12 led to a significant reduction in disease activity in multiple sclerosis patients. Moreover, the candidate had a favorable ...
Read more : Biogen files NDA for BG-12 | Views : 3347 | Replies : 8


FDA application for promising oral MS drug, BG-12

Image

Biogen Idec Inc., a Weston-based biotechnology company known for its multiple sclerosis drugs, said it has submitted a New Drug Application to federal regulators to get approval to market a potential new MS treatment known as BG-12.

In December, Biogen Idec shares hit their high for 2011 after the company released promising results from a clinical trial of BG-12.

BG-12, the company’s designation for dimethyl fumarate, would be taken twice a day in pill ...
Read more : FDA application for promising oral MS drug, BG-12 | Views : 1040 | Replies : 0




Oral MS drug BG-12 meets goal of CONFIRM trial

Image

Biogen Idec Inc's says its experimental multiple sclerosis drug BG-12 met the main goal of a closely watched clinical trial.

The Weston, Massachusetts-based biotechnology company said that a late-stage trial known as CONFIRM showed that BG-12, when given twice a day, cut the annualized relapse rate in patients with multiple sclerosis by 44 percent at two years versus placebo, and by 51 percent when given three times a day.

Investors had been waiting to ...
Read more : Oral MS drug BG-12 meets goal of CONFIRM trial | Views : 1004 | Replies : 0


Oral MS drug BG-12 significantly reduced MS relapses

Oral MS drug BG-12 significantly reduced MS relapses and disability progression

Image

Biogen Idec BIIB today announced positive data from the Phase 3 DEFINE clinical trial of oral BG-12 (dimethyl fumarate) in people with relapsing-remitting multiple sclerosis (RRMS).

Results showed that 240 mg of BG-12, administered either twice a day (BID) or three times a day (TID), significantly reduced the proportion of patients who relapsed by 49 percent and 50 percent, respectively, at two years ...
Read more : Oral MS drug BG-12 significantly reduced MS relapses | Views : 1124 | Replies : 1


MS drug BG-12 trial data reveals no safety surprises

Image

Detailed data from a key trial of Biogen Idec Inc's experimental multiple sclerosis drug BG-12 revealed no new safety concerns, and showed similar efficacy when given twice or three times a day, according to a summary of results to be presented at an upcoming conference.

Initial results from the trial, known as DEFINE, were released in April and showed the drug, when given twice a day, cut the annualized relapse rate by 53 percent ...
Read more : MS drug BG-12 trial data reveals no safety surprises | Views : 1165 | Replies : 0


Biogen faces key test with Phase 3 data on oral MS drug

Image

Can Biogen Idec keep the hits coming? The biotech giant's stock has been at the top of the charts among its peers over the past year, helped considerably by its experimental multiple sclerosis drug BG-12's performance in late-stage development.

With new Phase III data on the potential blockbuster expected within weeks, analysts told Reuters about some of the key factors that could play a role in the success of oral drug in the MS ...
Read more : Biogen faces key test with Phase 3 data on oral MS drug | Views : 927 | Replies : 1


 

Login  •  Register


Statistics

Total posts 216676 • Total topics 22135 • Total members 13921